Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists

Raven, Lisa M.; Muir, Christopher A.; Macdonald, Peter S.; Hayward, Chris; Jabbour, Andrew; Greenfield, Jerry R.

doi:10.1007/s00592-022-02018-3

Cited by 2 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTDM treatment vary by center, however, metformin remains first line therapy for HT recipients without CKD 62 . Newer agents, including sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 (GLP‐1) receptor agonists, have limited evidence in transplant recipients but are generally considered safe 63 …”

Section: Post‐transplant Health Maintenancementioning

confidence: 99%

“…62 Newer agents, including sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists, have limited evidence in transplant recipients but are generally considered safe. 63 There is no evidence for a target LDL after HT but many programs target goal LDL < 100 mg/dL or, in patients with CAV, DM, or other cardiovascular disease risk factors, aiming for LDL < 70 mg/dL. 6 Additional lipid lowering therapies such as ezetimibe, fish oil, and proprotein convertase subtilisn-kexin type 9 inhibitors (PCSK9i) can also be helpful in producing modest reduction in LDL.…”

Section: Optimization Of Cardiovascualar Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapy in the heart transplant recipient: A primer for nurse clinicians and pharmacists

Fraser,

Page,

Chow

et al. 2024

Clinical Transplantation

View full text Add to dashboard Cite

Heart transplantation (HT) is the definitive treatment for eligible patients with end‐stage heart disease. A major complication of HT is allograft rejection which can lead to graft dysfunction and death. The guiding principle of chronic immunosuppression therapy is to prevent rejection of the transplanted organ while avoiding oversuppression of the immune system, which can cause opportunistic infections and malignancy. The purpose of this review is to describe immunosuppressive management of the HT recipient—including agent‐specific pharmacology and pharmacokinetics, outcomes data, adverse effects, clinical considerations, and recent guideline updates. We will also provide recommendations for medical prophylaxis of immunosuppressed patients based on the most recent clinical guidelines. Additionally, we highlight the importance of medical therapy adherence and the effect of social determinants of health on the long‐term management of HT. HT recipients are a complex and high‐risk population. The objective of this review is to describe basic pharmacotherapy in HT and implications for nurses and pharmacists.

show abstract

Section: Post‐transplant Health Maintenancementioning

confidence: 99%